Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
Published version of a preprint
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Purpose: SET is an endogenous PP2A inhibitor that might represent a novel molecular target for antitumor therapy. The aim of this study was to evaluate the molecular effects of SET deregulation and its potential clinical significance in metastatic colorectal cancer (mCRC). Experimental Design: We studied the biologic effects of SET on cell growth, colonosphere formation, caspase activity, PP2A activation status, and sensitivity to oxaliplatin and FTY720 treatments. Moreover, we analyzed SET expression by immunostaining in 242 patients with mCRC. Results: SET deregulation promotes cell growth and colonosphere formation and inhibits PP2A, thereby impairing its antitumor effects. Moreover, SET reduces sensitivity to oxaliplatin in colorectal cancer cell lines, which is restored after FTY720 treatment. SET overexpression was detected in 24.8% (60 of 242) of patients with mCRC and determined significantly shorter overall (8.6 vs. 27 months; P < 0.001) and progression-free survival (7.1 vs. 13.7 months; P < 0.001), and poor response to oxaliplatin-based chemotherapy (P = 0.004). Interestingly, its prognostic value was particularly evident in patients younger than 70 years and in those harboring KRAS mutations. Conclusions: SET overexpression is a frequent event in mCRC that plays a potential oncogenic role associated with worse outcome and resistance to oxaliplatin. Moreover, this alteration defines a subgroup of patients who could benefit from therapies containing PP2A activators such as FTY720. Clin Cancer Res; 21(2); 347–56. ©2014 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mis- and dysregulation due to aberrant genes, post-translational modifications (PTMs), endogenous inhibitors, or disturbed protein interactions (Table 2 ) lead to impaired, incomplete, or dysfunctional PP2A activity, contributing to chronic diseases and carcinogenesis (Fig. 3 ) [ 101 – 103 ].”
From Targeting PP2A in cancer: an underrated option (2025) · cites this paper as [101]
In the citing paper
“PP2A dysregulation has also been documented in neuroblastoma and metastatic CRC, primarily due to the elevated levels of endogenous PP2A inhibitors CIP2A [ 110 ] and SET [ 101 ].”
From Targeting PP2A in cancer: an underrated option (2025) · cites this paper as [101]
Citations
Cites
Reporting Recommendations for Tumor Marker Prognostic Studies
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.0454 · Cited by 779 · cited 1×
“This work was carried out in accordance with Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines (36).”
MethodFan, Z., Beresford, P. J., Oh, D. Y., Zhang, D., & Lieberman, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00150-8 · Cited by 541
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Seo, S.-B., McNamara, P., Heo, S., Turner, A., Lane, W. S., & Chakravarti, D. (2001) · Cell · doi:10.1016/s0092-8674(01)00196-9 · Cited by 481
The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A
Li, M., Makkinje, A., & Damuni, Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11059 · Cited by 479
Neviani, P., Santhanam, R., Trotta, R., Notari, M., Blaser, B. W., Liu, S., Mao, H., Chang, J. S., Galietta, A., Uttam, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.015 · Cited by 476
PP2A: the expected tumor suppressor
Janssens, V., Goris, J., & Van Hoof, C. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.004 · Cited by 426
Protein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 2×
“Of importance, SET plays an oncogenic role modulating signaling pathways with high relevance in human cancer (11).”
BackgroundPP2A: Unveiling a Reluctant Tumor Suppressor
Mumby, M. (2007) · Cell · doi:10.1016/j.cell.2007.06.034 · Cited by 295
Cited by
Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 506
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
O’Connor, C. M., Perl, A., Leonard, D., Sangodkar, J., & Narla, G. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.008 · Cited by 190
“…expression of PP2A subunits, increased expression of endogenous PP2A inhibitors and changes in phosphorylation/methylation of the C subunit (Cristóbal et al., 2015; Ion Cristóbal et al., 2014; Haesen et al., 2016; Janghorban et al., 2014; Liu et al., 2015; Nobumori et al., 2013; Rincón et…”
BackgroundSelective PP2A enhancement through biased heterotrimer stabilization
Leonard, D., Huang, W., Izadmehr, S., O’Connor, C. M., Wiredja, D. D., Wang, Z., Zaware, N., Chen, Y., Schlatzer, D. M., Kiselar, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.038 · Cited by 176
Targeting PP2A in cancer: Combination therapies
Mazhar, S., Taylor, S. E., Sangodkar, J., & Narla, G. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.08.020 · Cited by 137
“Since SET expression modulated the response to these chemotherapeutic agents, the authors tested the combination of FTY720 with oxaliplatin or 5-Fluorouracil which resulted in enhanced efficacy in colorectal cancer cells [76].”
Background
Metadata
- Authors
- Cristóbal, I., Rincón, R., Manso, R., Caramés, C., Zazo, S., Madoz-Gúrpide, J., Rojo, F., & García-Foncillas, J.
- Affiliations
- Hospital Universitario Fundación Jiménez Díaz (ES)
- 2Pathology Department, IIS “Fundación Jiménez Diaz,” UAM, Madrid, Spain.
- 1Translational Oncology Division, Oncohealth institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital “Fundacion Jimenez Diaz,” Madrid, Spain.
- Venue
- Clinical Cancer Research
- Published
- 2015-01-14
- Volume
- 21
- Issue
- 2
- Pages
- 347-356
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2083832170
- Cited by
- 78
- References
- 41
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 11 · 2020: 4 · 2019: 11 · 2018: 10 · 2017: 5 · 2016: 8 · 2015: 5
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Instituto de Salud Carlos III
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- sets, PP2A inhibitors, metastatic colorectal cancer, oxaliplatin resistance, fingolimod, PP2A activation, prognostic factors, KRAS mutation, caspase activity, cell growth, chemotherapy response
- MeSH terms
- Oxaliplatin, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, DNA-Binding Proteins, Female, Humans, Liver Neoplasms, Male, Middle Aged, Organoplatinum Compounds, Retrospective Studies, Transcription Factors, Colorectal Neoplasms, Gene Expression, Proportional Hazards Models, Treatment Outcome, Disease-Free Survival, Drug Resistance, Neoplasm, Inhibitory Concentration 50, Cell Line, Tumor, Kaplan-Meier Estimate, Protein Phosphatase 2, Histone Chaperones, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0724
- The paper
- Cristóbal, I., Rincón, R., Manso, R., Caramés, C., Zazo, S., Madoz-Gúrpide, J., Rojo, F., & García-Foncillas, J. (2015). Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0724
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.